Relmada Therapeutics, Inc.
RLMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $16 | $31 | $26 | $79 |
| - Cash | $4 | $4 | $5 | $44 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $12 | $27 | $20 | $35 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$84 | $5 | -$161 | -$126 |
| % Margin | – | – | – | – |
| Net Income | -$80 | -$99 | -$157 | -$126 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.65 | -3.28 | -5.3 | -7.16 |
| % Growth | 19.2% | 38.1% | 26% | – |
| Operating Cash Flow | -$52 | -$52 | -$104 | -$92 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$52 | -$52 | -$104 | -$92 |